منابع مشابه
Bargaining and Delay in Patent Licensing
We consider a model of licensing of a non-drastic innovation in which the patent holder (an outside innovator) negotiates either up-front fixed fees or per-unit royalties with two firms producing horizontally differentiated brands and competing à la Cournot. We investigate how licensing schemes (fixed fee or per-unit royalty) and the number of licenses sold (exclusive licensing or complete tech...
متن کاملIntravenous Paracetamol and Patent Ductus Arteriosus Closure
Background: Standard medical treatments for patent ductus arteriosus (PDA) closure are, including indomethacin/ibuprofen and surgical ligation. Nowadays, a new strategy to close PDA is the use of paracetamol. The present study aimed to describe the use of intravenous (IV) paracetamol for PDA closure in neonates who present a contraindication to ibuprofen or ibuprofen failure with no possibility...
متن کاملPatent Theory versus Patent Law
According to the economic theory of patents, patents are needed so that pioneer firm have time to recoup their sunk costs of research and development. The key element in the economic theory is that pioneer firms have large, hard to recoup, sunk costs. Yet patents are not awarded on the basis of a firm’s sunk costs. Patent law, in fact, ignores costs. The disconnect between patent law and patent...
متن کاملPatent Number : United States Patent
J. J. Hopfield, “Neural Networks and Physical Systems with Emergent Collective Computational Abilities,” Proc. Nat. Acad. Sci., USA, vol. 79, pp. 2254-2258, Apr. 1982. R. J. McEliece, et al., “The Capacity of the Hopfield Associative Memory,” IEEE Transactions on Information Theory, vol. T-33, pp. 461-482, 1987. B. L. Montgomery et al., “Evaluation of the use of Hopfield Neural Network Model as...
متن کاملEU General Court Rules on Pay-for-Delay Agreements in Patent Disputes
• Type A: there is no restriction on the ability of the generic firm to market its product. • Type b-I: there is a restriction on the ability to market (e.g. non-challenge or non-infringement clause) but without any reverse payment. • Type b-II: there is a restriction on the ability to market and a reverse payment from the innovator company to the generic one (direct transfer of money, distribu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Intellectual Property Law & Practice
سال: 2008
ISSN: 1747-1532,1747-1540
DOI: 10.1093/jiplp/jpn204